Nanomedicine-based multidrug resistance reversal strategies in cancer therapy

Paliwal, Rishi; Paliwal, Shivani Rai; Kenwat, Rameshroo

doi:10.1016/b978-0-12-819793-6.00013-8

Cited by 2 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, treating ovarian cancer remains challenging with the currently available chemotherapeutic agents [ 4 , 5 ]. Combination and sequential treatment schedules of drug combinations is a common practice for managing recurrent ovarian cancer [ 4 , 5 , 10 , 11 ]. For example, one of the common sequences is first-line carboplatin and paclitaxel therapy followed by a re-treatment of both drugs at first relapse.…”

Section: Introductionmentioning

confidence: 99%

“…Drug resistance is attributed to several factors: drug inactivation by compartmentalization or detoxification, drug efflux, mutation or loss of drug targets, DNA repair, cell death inhibition, or alteration of apoptotic pathways. Additional factors can include tumor heterogeneity as well as angiogenesis [ 11 , 23 ]. Ovarian cancer cells are known to become resistant to a variety of drugs including cisplatin, carboplatin, and paclitaxel ( Figure 1 A) [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

“…Specifically, upregulation of ABC (adenosine triphosphate binding cassette) transporters, membrane proteins that regulate transport of substances across the cell membrane, increases drug efflux. This mechanism affects taxane agents but is not associated with low accumulation of platinum chemotherapeutics [ 11 , 17 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer

Levit

Tang

2021

Nanomaterials

View full text Add to dashboard Cite

Treatment of ovarian cancer is challenging due to late stage diagnosis, acquired drug resistance mechanisms, and systemic toxicity of chemotherapeutic agents. Combination chemotherapy has the potential to enhance treatment efficacy by activation of multiple downstream pathways to overcome drug resistance and reducing required dosages. Sequence of delivery and the dosing schedule can further enhance treatment efficacy. Formulation of drug combinations into nanoparticles can further enhance treatment efficacy. Due to their versatility, polymer-based nanoparticles are an especially promising tool for clinical translation of combination therapies with tunable dosing schedules. We review polymer nanoparticle (e.g., micelles, dendrimers, and lipid nanoparticles) carriers of drug combinations formulated to treat ovarian cancer. In particular, the focus on this review is combinations of platinum and taxane agents (commonly used first line treatments for ovarian cancer) combined with other small molecule therapeutic agents. In vitro and in vivo drug potency are discussed with a focus on quantifiable synergistic effects. The effect of drug sequence and dosing schedule is examined. Computational approaches as a tool to predict synergistic drug combinations and dosing schedules as a tool for future nanoparticle design are also briefly discussed.

show abstract